Phospho-specific antibodies to Flt3 and uses thereof
US7183385B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2003 |
| Grant date | Feb 27, 2007 |
| Priority date | — |
| Expiry date | Apr 23, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention discloses two newly-discovered Flt3 phosphorylation sites, tyrosine 589 (Tyr589) and tyrosine 591 (Tyr591) in the intracellular domain, and provides antibodies, both polyclonal and monoclonal, that selectively bind to Flt3 when phosphorylated at these novel sites. Also provided are assays utilizing these reagents, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibodies, that binds to Flt3 when phosphorylated at Tyr589 or Tyr591. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.